| 000 | 02830 a2200781 4500 | ||
|---|---|---|---|
| 005 | 20250515031809.0 | ||
| 264 | 0 | _c20060821 | |
| 008 | 200608s 0 0 eng d | ||
| 022 | _a1527-7755 | ||
| 024 | 7 |
_a10.1200/JCO.2005.03.6640 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWu, Xifeng | |
| 245 | 0 | 0 |
_aGenetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. _h[electronic resource] |
| 260 |
_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _cAug 2006 |
||
| 300 |
_a3789-98 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdenocarcinoma _xdrug therapy |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xgenetics |
| 650 | 0 | 4 |
_aCarcinoma, Squamous Cell _xdrug therapy |
| 650 | 0 | 4 | _aChemotherapy, Adjuvant |
| 650 | 0 | 4 | _aCritical Pathways |
| 650 | 0 | 4 |
_aDNA-Binding Proteins _xgenetics |
| 650 | 0 | 4 | _aDose Fractionation, Radiation |
| 650 | 0 | 4 |
_aEsophageal Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aEsophagectomy _xmethods |
| 650 | 0 | 4 | _aEsophagogastric Junction |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFluorouracil _xadministration & dosage |
| 650 | 0 | 4 | _aGenes, MDR |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMethylenetetrahydrofolate Reductase (NADPH2) _xgenetics |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoadjuvant Therapy _xmethods |
| 650 | 0 | 4 | _aOdds Ratio |
| 650 | 0 | 4 |
_aPlatinum Compounds _xadministration & dosage |
| 650 | 0 | 4 | _aPolymorphism, Single Nucleotide |
| 650 | 0 | 4 | _aPredictive Value of Tests |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 | _aRadiotherapy, Adjuvant |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 |
_aStomach Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 |
_aTaxoids _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aX-ray Repair Cross Complementing Protein 1 |
| 700 | 1 | _aGu, Jian | |
| 700 | 1 | _aWu, Tsung-Teh | |
| 700 | 1 | _aSwisher, Stephen G | |
| 700 | 1 | _aLiao, Zhongxin | |
| 700 | 1 | _aCorrea, Arlene M | |
| 700 | 1 | _aLiu, Jun | |
| 700 | 1 | _aEtzel, Carol J | |
| 700 | 1 | _aAmos, Christopher I | |
| 700 | 1 | _aHuang, Maosheng | |
| 700 | 1 | _aChiang, Silvia S | |
| 700 | 1 | _aMilas, Luke | |
| 700 | 1 | _aHittelman, Walter N | |
| 700 | 1 | _aAjani, Jaffer A | |
| 773 | 0 |
_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 24 _gno. 23 _gp. 3789-98 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1200/JCO.2005.03.6640 _zAvailable from publisher's website |
| 999 |
_c16379701 _d16379701 |
||